Table 2.
FDA Approved HCC Drugs And Their Molecular Targets
| Drug | Application | Approval Time | Target | Reference |
|---|---|---|---|---|
| Sorafenib | First-line | 2007 | VEGFR1-3 and PDGFR | 62 |
| Lenvatinib | First-line | 2018 | VEGFR1-3,FGFR1-4, PDGFR-α, KIT and RET | 71 |
| Regorafenib | Second-line | 2017 | VEGFR1-3, c-TKITIE-2, PDGFR-β, FGFR-1, RET, c-RAF, BRAF and p38MAP kinase | 75 |
| Cabozantinib | Second-line | 2019 | VEGFR, MET, and AXL | 78 |
| Ramucirumab | Second-line | 2019 | VEGFR-2 | 97 |
| Nivolumab | Second-line | 2017 | Human immunoglobulin G4 anti-PD-1 monoclonal antibody | 124 |
| Pembrolizumab | Second-line | 2018 | PD-1 check point | 91 |
Abbreviations: FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; PD-1, programmed cell death protein 1.